COGT241220C5000
- 5.60
- 0.000.00%
Cogent Biosciences Newsroom
Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15
Needham Downgrades Cogent Biosciences(COGT.US) to Hold Rating, Maintains Target Price $15
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Cogent Biosciences Price Target Maintained With a $15.00/Share by Needham
Cogent Biosciences Analyst Ratings
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $16
Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of Bezuclasinib
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Cogent Biosciences Is Maintained at Buy by Needham
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15
Cogent Biosciences Analyst Ratings
Cogent Biosciences: Buy Rating Affirmed Amid Anticipation for Bezuclastinib Data and Strong Financial Position
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences